Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 7/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.43 |
| ▸ | PIM1 | P11309 | 2/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8960 | 1.00 | SRC (0.52) | SRCTNFSF11SLC2A1ALKPARP1 | |
| SCHEMBL1998529 | 0.94 | SLC2A1 (0.54) | SRCTNFSF11SLC2A1PARP1CHEK1 | |
| SCHEMBL4018984 | 0.91 | SLC2A1 (0.46) | SRCTNFSF11SLC2A1ALKPARP1 | |
| SCHEMBL3725738 | 0.91 | SLC2A1 (0.46) | SRCTNFSF11SLC2A1ALKPARP1 | |
| SCHEMBL6253346 | 0.89 | SRC (0.52) | SRCSLC2A1ALKPARP1CHEK1 | |
| SCHEMBL8917 | 0.88 | SRC (0.63) | SRCSLC2A1PARP1CHEK1PIM1 | |
| SCHEMBL3231833 | 0.86 | SLC2A1 (0.47) | SRCSLC2A1PARP1CHEK1PIM1 | |
| SCHEMBL17967511 | 0.85 | SRC (0.49) | SRCSLC2A1ALKPARP1CHEK1 | |
| SCHEMBL27576840 | 0.84 | SLC2A1 (0.50) | SRCSLC2A1PARP1CHEK1PIM1 | |
| SCHEMBL13090425 | 0.84 | SLC2A1 (0.50) | SLC2A1PARP1CHEK1PIM1RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2956138-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA PHARMACEUTICALS INC (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20210393641-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | OXFORD FINANCE LLC | 2021-12-23 | — | — | US | disclosed |
| US-10966987-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| CN-107674059-B | Benzaheteroaromatic ring compound and preparation method and application thereof | 中国药科大学 | 2020-04-14 | — | — | CN | disclosed |
| US-20200054644-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2020-02-20 | — | — | US | disclosed |
| US-10398703-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180133225-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2018-05-17 | — | — | US | disclosed |
| US-9877970-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9827248-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160235761-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2016-08-18 | — | — | US | disclosed |
| WO-2002000644-A1 | GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | ASTRAZENECA AB (SE) | 2002-01-03 | — | — | WO | disclosed |
| WO-2001066099-A2 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2001-09-13 | — | — | WO | disclosed |
| US-6184225-B1 | ENDOTHELIAL GROWTH FACTOR INHIBITORS, ANGIOGENESIS INHIBITORS | ZENECA LIMITED (GB) | 2001-02-06 | — | — | US | disclosed |
| WO-2001004102-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 2001-01-18 | — | — | WO | disclosed |
| EP-0790986-B1 | ANILINE DERIVATIVES | ZENECA LTD (GB) | 1999-01-20 | — | — | EP | disclosed |
| EP-0880508-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ZENECA LIMITED (GB) | 1998-12-02 | — | — | EP | disclosed |
| US-5821246-A | USEFUL AS TYROSINE KINASE INHIBITORS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | ZENECA LIMITED (GB) | 1998-10-13 | — | — | US | disclosed |
| EP-0790986-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-27 | — | — | EP | disclosed |
| WO-1997030035-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ZENECA LIMITED (GB) | 1997-08-21 | — | — | WO | disclosed |
| WO-1996015118-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10966987-B2 | Therapeutic compounds and uses thereof | MUC1, CFTR, SLC26A4 | SRC 4259/4885TNFSF11 4206/4885SLC2A1 700/4885 |
| US-20210393641-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | SRC 4259/4885TNFSF11 4206/4885SLC2A1 700/4885 |
| US-20200054644-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | SRC 4259/4885TNFSF11 4206/4885SLC2A1 700/4885 |
| US-20180133225-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | SRC 4259/4885TNFSF11 4206/4885SLC2A1 700/4885 |
| US-20160235761-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | SRC 4259/4885TNFSF11 4206/4885SLC2A1 700/4885 |
| US-10398703-B2 | Therapeutic compounds and uses thereof | MUC1, CFTR, SLC26A4 | SRC 4259/4885TNFSF11 4206/4885SLC2A1 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.